异动分析 医疗器械概念+辅助生殖+人民币贬值受益 来源：新浪证券-红岸工作室 9月26日，采纳股份跌1.25%，成交额4813.76万元，换手率2.60%，总市值29.90亿元。 1、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 2、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-187.34万，占比0.04%，行业排名70/131，连续2日被主力资金减仓；所属行业主力净流 入-6.04亿，当前无连续增减仓现象，主力趋势不明显。 区间今日近3日近5日近10日近20日主力净流入-187.34万-741.67万-2607.78万-4266.65万-4035.66万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额3092.47万，占总成交额的8.28%。 技术面：筹码平均交易成本为23.47元 该股筹码平均交易成本为23 ...

9月25日，采纳股份跌2.86%，成交额5456.05万元。两融数据显示，当日采纳股份获融资买入额554.53 万元，融资偿还990.42万元，融资净买入-435.90万元。截至9月25日，采纳股份融资融券余额合计 7801.35万元。 融资方面，采纳股份当日融资买入554.53万元。当前融资余额7801.35万元，占流通市值的2.58%，融资 余额超过近一年90%分位水平，处于高位。 融券方面，采纳股份9月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年70%分位水平，处于较高位。 资料显示，采纳科技股份有限公司位于江苏省江阴市华士镇澄鹿路253号，成立日期2004年7月23日，上 市日期2022年1月26日，公司主营业务涉及医用和兽用注射穿刺器械及实验室耗材的研发、生产和销 售。主营业务收入构成为：注射器45.17%，穿刺针45.01%，实验室耗材5.49%，其他4.33%。 截至9月19日，采纳股份股东户数6901.00，较上期减少11.17%；人均流通股10960股，较上期增加 12.58%。2025年1月-6月， ...

分红方面，采纳股份A股上市后累计派现1.55亿元。近三年，累计派现1.22亿元。 责任编辑：小浪快报 资料显示，采纳科技股份有限公司位于江苏省江阴市华士镇澄鹿路253号，成立日期2004年7月23日，上 市日期2022年1月26日，公司主营业务涉及医用和兽用注射穿刺器械及实验室耗材的研发、生产和销 售。主营业务收入构成为：注射器45.17%，穿刺针45.01%，实验室耗材5.49%，其他4.33%。 截至9月10日，采纳股份股东户数7769.00，较上期增加4.82%；人均流通股9736股，较上期减少4.60%。 2025年1月-6月，采纳股份实现营业收入1.58亿元，同比减少18.54%；归母净利润936.94万元，同比减少 71.78%。 9月15日，采纳股份涨1.28%，成交额9768.30万元。两融数据显示，当日采纳股份获融资买入额1409.42 万元，融资偿还935.43万元，融资净买入473.99万元。截至9月15日，采纳股份融资融券余额合计 7095.01万元。 融资方面，采纳股份当日融资买入1409.42万元。当前融资余额7095.01万元，占流通市值的2.30%，融 资余额超过近一年80%分 ...

Core Viewpoint - The company, Canar Medical, is experiencing a decline in stock price and revenue, while benefiting from the depreciation of the RMB due to its high overseas revenue proportion. Group 1: Company Overview - Canar Medical specializes in the research, production, and sales of injection and puncture instruments, as well as laboratory consumables, with main products including puncture needles, syringes, laboratory consumables, and masks [2][8] - The company began supplying IVF culture tube products to Thermo Fisher in 2018 [3] - As of August 20, the number of shareholders in Canar Medical is 8,029, a decrease of 4.54% from the previous period, with an average of 9,420 circulating shares per shareholder, an increase of 4.76% [8] Group 2: Financial Performance - For the first half of 2025, Canar Medical reported revenue of 158 million yuan, a year-on-year decrease of 18.54%, and a net profit attributable to shareholders of 9.37 million yuan, down 71.78% year-on-year [8] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [9] Group 3: Market Dynamics - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the RMB [4] - The stock price of Canar Medical has recently decreased by 1.88%, with a trading volume of 97.35 million yuan and a turnover rate of 5.91%, resulting in a total market capitalization of 2.677 billion yuan [1]

Core Viewpoint - The stock price of Canar Medical Co., Ltd. closed at 24.22 yuan on August 20, 2025, reflecting a decrease of 0.14 yuan or 0.57% from the previous trading day [1] Company Overview - Canar Medical operates in the medical device sector, focusing on the research, production, and sales of medical products, veterinary products, and laboratory consumables [1] - In the 2024 annual report, medical products accounted for 51.23% of the company's revenue, while veterinary products made up 39.03% [1] Recent Developments - On August 20, 2025, Canar Medical announced that its wholly-owned subsidiary, Jiangsu Canar Medical Technology Co., Ltd., received three utility model patent certificates from the National Intellectual Property Administration. The patents include "a pressure-resistant anti-backflow infusion pipeline," "a pressure display syringe," and "a fixed measurement syringe," all of which are related to the company's main business products [1] Financial Performance - On August 20, 2025, the main funds experienced a net outflow of 716,700 yuan, with a cumulative net outflow of 4,222,500 yuan over the past five days [1]

Group 1 - The core point of the article is that Canar Medical Technology Co., Ltd., a wholly-owned subsidiary of Canar Co., has recently received patent certificates from the National Intellectual Property Administration for three medical products [2] - The patents granted include "a pressure-resistant anti-backflow infusion pipeline," "a pressure display syringe," and "a fixed measurement syringe" [2] - For the fiscal year 2024, Canar's revenue composition is as follows: medical products account for 51.23%, veterinary products for 39.03%, laboratory consumables for 7.61%, and others for 2.13% [2]

序号股票简称PE(TTM)PE(静)市净率总市值(元)13采纳股份85.1357.281.6730.41亿行业平均 56.5652.664.92118.97亿行业中值39.7639.192.9457.67亿1九安医疗11.2811.400.89190.28亿2英科医疗 15.1416.331.35239.25亿3山东药玻16.1616.211.86152.83亿4振德医疗16.7615.801.0760.86亿5新华医疗 17.1715.911.40110.05亿6奥美医疗17.1816.831.7762.06亿7九强生物17.8916.632.1988.59亿8康德莱 18.3218.341.5239.49亿9维力医疗18.6219.892.3443.64亿10奥泰生物18.7119.731.5159.67亿11鱼跃医疗 20.1519.762.72356.78亿12三鑫医疗20.8121.623.6549.16亿 来源：金融界 采纳科技股份有限公司的主营业务是注射穿刺器械及实验室耗材的研发、生产和销售。公司的主要产品 是医疗器械、动物器械、实验室耗材等。公司被认定为江苏省专精特新中小企业、农业产业化省级龙 ...

8月1日，采纳股份今日收盘23.56元，上涨3.38%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到80.61倍，创91天以来新低，总市值28.80亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13采纳股份80.6154.251.5828.80亿行业平均 53.6550.024.68114.74亿行业中值37.2237.112.6755.30亿1九安医疗11.0111.130.87185.78亿2英科医疗 15.4516.651.37244.06亿3新华医疗15.7214.571.28100.77亿4山东药玻16.0216.071.84151.57亿5振德医疗 16.2915.351.0459.13亿6奥美医疗16.4116.081.6959.27亿7九强生物17.4416.212.1486.36亿8康德莱 17.6117.631.4637.96亿9维力医疗17.6918.902.2341.47亿10奥泰生物18.1519.141.4757.89亿11鱼跃医疗 19.8419.462.68351.37亿12安图生物20.0619.152.58228.74亿 来源：金融界 从行业 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Canan Technology Co., Ltd. in the medical device industry, noting its current stock price and market capitalization [1][2] - As of July 24, the stock price of Canan Technology closed at 23.27 yuan, reflecting a 3.51% increase, with a rolling PE ratio of 79.62, marking a new low in 84 days, and a total market value of 2.845 billion yuan [1] - The average PE ratio for the medical device industry is 54.55, with a median of 37.54, positioning Canan Technology at the 100th rank within the industry [1][2] Group 2 - In terms of capital flow, on July 24, Canan Technology experienced a net inflow of 10.8779 million yuan, with a total inflow of 1.5107 million yuan over the past five days [1] - The company specializes in the research, production, and sales of injection puncture instruments and laboratory consumables, recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest financial results for the first quarter of 2025 show that Canan Technology achieved an operating income of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34%, with a gross profit margin of 31.15% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Canar Medical Co., which has a current PE ratio of 77.63, marking a new low in 78 days, with a total market capitalization of 2.774 billion yuan [1][2] - Canar Medical's main business includes the research, production, and sales of injection and puncture instruments and laboratory consumables, and it has been recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province [1] - The latest quarterly report for Q1 2025 shows that Canar Medical achieved operating revenue of 72.7093 million yuan, a year-on-year decrease of 34.28%, and a net profit of 7.6802 million yuan, down 69.34% year-on-year, with a gross profit margin of 31.15% [1] Group 2 - In terms of industry comparison, the average PE ratio for the medical device industry is 52.71, with a median of 37.14, positioning Canar Medical at the 98th rank within the industry [1][2] - The number of shareholders for Canar Medical has increased to 7,596, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1]